Insulin Degludec/Insulin Aspart (IDegAsp) Provides Superior FPG Control and Reduced Hypoglycaemia vs. Biphasic Insulin Aspart 30 (BIAsp 30) in Insulin-Naive Adults with Type 2 Diabetes in a Randomized Phase 3 Trial

被引：0
|
作者：
Franek, Edward
Haluzik, Martin
Canecki-Varzic, Silvija
Sargin, Mehmet
Macura, Stanislava
Zacho, Jeppe
Christiansen, Jens Sandahl
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
882-P
引用
收藏
页码：A225 / A225
页数：1
相关论文
共 50 条
  • [1] IDegAsp provides superior FPG control and reduced hypoglycaemia vs BIAsp 30 in insulin-naive adults with type 2 diabetes: a randomised phase 3 trial
    Franek, E.
    Haluzik, M.
    Varzic, S. Canecki
    Sargin, M.
    Macura, S.
    Zacho, J.
    Christiansen, J.
    [J]. DIABETOLOGIA, 2014, 57 : S380 - S380
  • [2] IDEGASP PROVIDES SUPERIOR FPG CONTROL AND REDUCED HYPOGLYCEMIA VS BIASP 30 IN INSULIN-NAIVE ADULTS WITH TYPE 2 DIABETES: A RANDOMIZED PHASE 3 TRIAL
    Franek, E.
    Haluzik, M.
    Canecki-Varzic, S.
    Sargin, M.
    Macura, S.
    Zacho, J.
    Christiansen, J. Sandahl
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S166 - S167
  • [3] Insulin Degludec/Insulin Aspart (IDegAsp) Twice Daily (BID) vs. Biphasic Insulin Aspart 30 (BIAsp 30) BID-A Randomized Trial in Chinese Patients with Type 2 Diabetes
    Yang, Wenying
    Ma, Jianhua
    Hong, Tianpei
    Liu, Ming
    Miao, Heng
    Peng, Yongde
    Wang, Changjiang
    Xu, Xiangjin
    Yang, Tao
    Nielsen, Anne Moeller
    Pan, Lili
    Liu, Weihong
    Zhao Weigang
    [J]. DIABETES, 2018, 67
  • [4] Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naive adults with Type 2 diabetes
    Franek, E.
    Haluzik, M.
    Varzic, S. Canecki
    Sargin, M.
    Macura, S.
    Zacho, J.
    Christiansen, J. S.
    [J]. DIABETIC MEDICINE, 2016, 33 (04) : 497 - 505
  • [5] Insulin degludec/insulin aspart (IDegAsp) twice daily (BID) vs biphasic insulin aspart 30 (BIAsp 30) BID: a randomised trial in Chinese patients with type 2 diabetes
    Ma, J.
    Yang, W.
    Hong, T.
    Liu, M.
    Miao, H.
    Peng, Y.
    Wang, C.
    Xu, X.
    Yang, T.
    Liu, W.
    Nielsen, A. Moeller
    Pan, L.
    Weigang, Z.
    [J]. DIABETOLOGIA, 2018, 61 : S410 - S411
  • [6] Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
    Onishi, Yukiko
    Yamada, Kenichi
    Zacho, Jeppe
    Ekelund, Jan
    Iwamoto, Yasuhiko
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2017, 8 (02) : 210 - 217
  • [7] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/INSULIN ASPART (IDEGASP) COMPARED WITH BIPHASIC INSULIN ASPART (BIASP 30) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A MEXICAN HEALTHCARE PERSPECTIVE
    Sanchez-Pedraza, V
    Hansen, B. B.
    Gundgaard, J.
    Uranga Romano, Garca J.
    Evans, M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A672 - A672
  • [8] IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, in type 2 diabetes: comparison with biphasic insulin aspart 30
    Vaag, A.
    Leiter, L. A.
    Franek, E.
    Weng, J.
    Damci, T.
    Munoz Torres, M.
    Donnet, J. -P.
    Endahl, L.
    Skjoth, T.
    Niskanen, L.
    [J]. DIABETOLOGIA, 2011, 54 : S423 - S423
  • [9] Biphasic Insulin Aspart 30 (BIAsp 30) is Safe and Improves Glycaemic Control in Insulin Naive Patients with Type 2 Diabetes
    Esteghamati, Alireza
    Nakhjavani, Manouchehr
    Aminorroaya, Ashraf
    Aboutorabi, Robabeh
    Niafar, Mitra
    Mohammadi, Mohammad
    Parvaresh, Ehsan
    [J]. JOURNAL OF DIABETES & METABOLISM, 2011, 2 (03)
  • [10] Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
    Niskanen, Leo
    Leiter, Lawrence A.
    Franek, Edward
    Weng, Jianping
    Damci, Taner
    Munoz-Torres, Manuel
    Donnet, Jean-Paul
    Endahl, Lars
    Skjoth, Trine Vang
    Vaag, Allan
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 167 (02) : 287 - 294
12345